Term
Cyclosporine:
- MOA
- Clinical use
- Toxicity |
|
Definition
MOA: Binds cyclophilins, inhibits calcineurin which blocks T cell activation and differentiation--> prevents IL-2 production
For: immunosupression (post. transplant and autoimmune disorders)
Tox: predisposition for viral infections and lymphoma, nephrotoxic, and gout
|
|
|
Term
Tacrolimus (FK506):
- MOA
- Clinical use
- Toxicity |
|
Definition
MOA: binds to FK-binding protein to inhibit secretion of IL-2 (and other cytokines)
For: immunosuppression (post. transplant and autoimmune disorders)
Tox: high nephrotoxicity, peripheral neuropathy, hypertension, pleural effusion, hyperglycemia |
|
|
Term
Sirolimus (Rapamycin):
- MOA
- Clinical use
- Toxicity |
|
Definition
MOA: inhibits mTOR, inhibits T-cell proliferation in response to IL-2
For: Immunosupression post kidney transplant (along with cyclosporine and corticosteroids)
Tox: Hyperlipidemia, thrombocytopenia, leukopenia |
|
|
Term
Azathioprine:
- MOA
- Clinical use
- Toxicity |
|
Definition
MOA: Toxic to proliferating lymphocytes b/c it interferes with metabolism and synthesis of nucleic acids
For: Post. kidney transplant and autoimmune disorders
Tox: Bone marrow suppression. More toxic when combined with allopurinol (for gout) b/c it's active metabolite (mercaptopurine) is metabolized by xanthine oxidase. |
|
|
Term
Muromonab-CD3 (OKT3):
- MOA
- Clinical use
- Toxicity |
|
Definition
MOA: a monoclonal antibody that binds and blocks CD3 on T cells, so no T-cell signal transduction
For: Immunosuppression post. kidney transplant
Tox: cytokine release syndrome, hypersensitivity reaction |
|
|
Term
Clinical use of Aldesleukin
|
|
Definition
| Recombinant IL-2 that treats renal cell carcinoma and metastatic melanoma |
|
|
Term
| Clinical use of Filgrastim |
|
Definition
| Is a recombinant cytokine that helps with recovery of bone marrow |
|
|
Term
| Clinical use of Sargramostim |
|
Definition
| Is a recombinant cytokine that helps with recovery of bone marrow |
|
|
Term
| Clinical use of recombinant α-interferon |
|
Definition
| Treats Hep. B and C, Kaposi's sarcoma, leukemias, and malignant melanoma |
|
|
Term
| Clinical use of recombinant β-interferon |
|
Definition
| Treats multiple sclerosis |
|
|
Term
| Clinical use of recombinant γ-interferon |
|
Definition
| Treats chronic granulomatous disease |
|
|
Term
| Clinical use of Oprelvekin |
|
Definition
| A recombinant IL-1 that treats thrombocytopenia |
|
|
Term
| Target and Clinical Use of Daclizumab |
|
Definition
| A monoclonal antibody that binds to the IL-2 receptor on activated T cells to prevent acute rejection of renal transplants |
|
|
Term
| Target and Clinical Use of Infliximab |
|
Definition
| Is a monoclonal antibody against TNF-α used to treat Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis |
|
|
Term
| Target and Clinical Use of Adalimumab |
|
Definition
| Is a monoclonal antibody against TNF-α used to treat Crohn's disease, rheumatoid arthritis, and psoriatic arthritis |
|
|
Term
| Target and Clinical Use of Abciximab |
|
Definition
| Is a monoclonal antibody against Glycoprotein IIb/IIIa that's used to prevent cardiac ischemia in unstable angina |
|
|
Term
| Target and Clinical Use of Tratuzumab (Herceptin) |
|
Definition
| Is a monoclonal antibody against erb-B2 used to treat HER-2 over-expressing breast cancer |
|
|
Term
| Target and Clinical Use of Rituximab |
|
Definition
| Is a monoclonal antibody against CD20 that's used to treat B-cell non-Hodgkin's lymphoma |
|
|
Term
| Target and Clinical Use of Omalizumab |
|
Definition
| Is a monoclonal antibody against IgE that is used as an additional line of treatment against severe asthma |
|
|
